United Therapeutics (UTHR) Revenue Growth (1y) (2010 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Revenue Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.70 Bn | 621.95 Bn | 17.26 Bn | 6.60% |
| 2 | AbbVie | 440.80 Bn | 434.23 Bn | 12.70 Bn | 10.16% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 5.07% |
| 4 | Novartis Ag | 266.37 Bn | 258.68 Bn | 11.24 Bn | 2.52% |
| 5 | Pfizer | 158.89 Bn | 147.19 Bn | 10.94 Bn | 2.60% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 19.16% |
| 7 | Revolution Medicines | 44.38 Bn | 44.38 Bn | - | - |
| 8 | Incyte | 25.28 Bn | 20.74 Bn | 1.57 Bn | 37.72% |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | -1.92% |
| 10 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 39.49% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.92% |
| Mar 31, 2026 | -1.62% |
| Dec 31, 2025 | 7.38% |
| Sep 30, 2025 | 6.76% |
| Jun 30, 2025 | 11.71% |
| Mar 31, 2025 | 17.22% |
| Dec 31, 2024 | 19.72% |
| Sep 30, 2024 | 22.89% |
| Jun 30, 2024 | 19.85% |
| Mar 31, 2024 | 33.70% |
| Dec 31, 2023 | 25.07% |
| Sep 30, 2023 | 18.10% |
| Jun 30, 2023 | 27.76% |
| Mar 31, 2023 | 9.74% |
| Dec 31, 2022 | 18.38% |
| Sep 30, 2022 | 16.03% |
| Jun 30, 2022 | 4.57% |
| Mar 31, 2022 | 21.84% |
| Dec 31, 2021 | 7.87% |
| Sep 30, 2021 | 17.00% |